09:36 CHINA HEALTH<00673> - Announcement & Resumption (4) No. of Shares swissfirst (Lie) Opportunities Anlagegesellschaft AG 28,103,000 12.95% 28,103,000 11.99% 28,103,000 11.03% swissfirst Structured Bonds AG 1,236,000 0.57% 18,536,000 7.91% 18,536,000 7.28% (Note 1) Guo Kang Pharmaceutical & Medical Supplies Ltd. 17,000,000 7.83% 17,000,000 7.25% 17,000,000 6.67% Directors of the Company Dr. Li Zhong Yuan (Note 2) 21,902,000 10.09% 21,902,000 9.35% 21,902,000 8.60% Dr. Ni Aimin 750,000 0.35% 750,000 0.32% 750,000 0.29% Mr. Lee Jong Dae 3,026,500 1.39% 3,026,500 1.29% 3,026,500 1.19% Mr. Deng Ku Hon 432,000 0.20% 432,000 0.18% 432,000 0.17% Mr. Robin Willi 912,000 0.42% 912,000 0.39% 912,000 0.36% Mr. Martin Treffer (Note 3) 1,545,000 0.71% 1,545,000 0.66% 1,545,000 0.61% Bondholders - - - - 20,388,118 8.00% Public 142,161,077 65.49% 142,161,077 60.66% 142,161,077 55.80% 217,067,577 100.00% 234,367,577 100.00% 254,755,695 100.00% Notes: 1. Including 17,300,000 new Shares to be issued upon conversion of the Existing Bonds at the conversion price of HK$1.00 each (subject to adjustment). 2. 11,147,000 Shares are held by Pacific Annex Capital Limited and 6,120,000 Shares are held by Timenew Limited, both companies are wholly-owned by Dr. Li Zhong Yuan. 3. 1,295,000 Shares are held by 2 Trade Group Limited which is owned as to 35% by Mr. Martin Treffer. 4. On the basis that the Convertible Bonds with an aggregate principal amount of US$6.6 million have all been converted at the Conversion Price of HK$2.525 per Conversion Share and the Company has not issued any new Shares other than those to be issued upon conversion of the Existing Bonds. Apart from the Convertible Bonds, the Existing Bonds and the Share Options, the Company does not have any other outstanding option, right or warrant which is convertible into or exercisable or exchangeable for the Shares. 3. NET PROCEEDS, REASONS FOR THE ISSUE OF CONVERTIBLE BONDS AND USE OF PROCEEDS The net proceeds from the issue of the Convertible Bonds are estimated to be approximately US$6.47 million. The aggregate expenses relating to the issue of the Convertible Bonds amount to approximately US$130,000 and include commission payable to the Agent, legal and professional fees, printing and other ancillary expenses. Commission payable to the Agent amounts to US$61,500, which represents 1% of the gross proceeds raised by it. The Agent is independent of and not connected with the Company or its connected persons, and is not a connected person of the Company. The Directors consider that in view of the existing capital structure of the Group, the issue of the Convertible Bonds provides a flexible and cost-efficient funding opportunity which is in the best interest of the